SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease


About this study

To investigate the efficacy of the administration of JVS-100 delivered via direct intramuscular injections on a 3 month and 6 month composite endpoint of wound progression, healing and limb loss in patients with severe peripheral arterial disease with non-healing chronic wounds who undergo an open bypass grafting or endovascular procedure for treatment of infrapopliteal disease and are dosed within 2 days and 3 months following the procedure.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18 to 85 inclusive, currently receiving standard of care wound treatment for chronic wounds or gangrene including as indicated:
    • debridement,
    • pressure offloading,
    • infection control, and/or
    • maintenance of a moist wound environment.
  • Diagnosis of advanced peripheral artery disease (PAD) with tissue loss (ulceration and/or dry gangrene)
  • Post intervention inclusion criteria include a successful open bypass grafting or endovascular intervention of an infrapopliteal lesion(s) on the same leg that has tissue loss without significant improvement in toe brachial index (TBI) post intervention. The following will be accepted as demonstrating a lack of post intervention toe brachial index (TBI) improvement:
    • toe brachial index (TBI) ≤ 0.51
    • Toe pressure < 50 mmHg with flat or dampened wave forms
    • Skin Perfusion pressure < 40 mmHg at mid foot level

Exclusion Criteria:

  • Previous major amputation of the leg to be treated or planned major amputation or transmetatarsal amputation within the first month following enrollment.
  • Only a short segment superficial femoral artery lesion - consistent with Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) A or B category, and no infrapopliteal disease
  • Staged or planned intervention in the index leg within 30 days after the index procedure
  • Acute limb-threatening ischemia, trauma, known non-atherosclerotic vascular disease
  • Non-salvageable limb defined as major tissue loss and an unsalvageable foot;
  • Clinical evidence of invasive infection in the index leg
  • Inability to safely perform a revascularization procedure due to uncontrolled diabetes or other medical condition.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Sanjay Misra, M.D.

Closed for enrollment

More information


Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions